Description
SANA (salicylic acid nitroalkene) is a synthetic small molecule research compound representing a first-in-class member of a novel nitroalkene-based chemistry class investigated for metabolic research applications. Recently characterized in the academic research literature — including a Phase 1a/b clinical research study published in Nature Metabolism (2024) — SANA has been investigated as a research tool for creatine-dependent thermogenesis pathway research, mitochondrial respiration research, and adipose tissue metabolic research. Unlike earlier generations of metabolic research compounds, SANA has been characterized as operating through mechanisms independent of UCP1 (uncoupling protein 1) and AMPK (AMP-activated protein kinase) pathways — the two most extensively-studied traditional targets in metabolic research pharmacology. This mechanism differentiation makes SANA a research tool of significant academic interest for investigating novel metabolic pathway research beyond traditional UCP1/AMPK-mediated thermogenesis. The compound is offered here strictly for laboratory research applications investigating creatine-dependent thermogenesis pharmacology, mitochondrial respiration research, and comparative pharmacology across the broader metabolic research compound class. SANA remains an early-stage investigational research compound without regulatory approval anywhere in the world.
Benefits (Research Focus)
• Creatine-dependent thermogenesis research — studied as a first-in-class research tool for the novel creatine-dependent thermogenesis pathway in adipose tissue research models
• Mitochondrial respiration research — investigated for enhancement of mitochondrial respiration and fat oxidation endpoints in adipose tissue research models
• UCP1/AMPK-independent mechanism research — explored as a research compound operating independently of the traditional UCP1 and AMPK metabolic pathways
• Nitroalkene chemistry research — examined as a novel salicylic acid-nitroalkene small molecule for structure-activity relationship research
• Comparative metabolic research — researched alongside other metabolic research compounds for comparative pharmacology and mechanism differentiation studies
What Researchers Look At
• Creatine-dependent thermogenesis pathway markers in adipose tissue research models
• Mitochondrial respiration endpoints and fat oxidation markers in cell research
• Liver fat markers and insulin sensitivity endpoints in preclinical research models
• Comparative pharmacology versus UCP1-dependent and AMPK-dependent research compounds
• Structure-activity relationships of nitroalkene functional group chemistry in small-molecule metabolic research
Quick Specs
• Form: Gelatin capsule
• Strength: 100 mg SANA per capsule
• Quantity: 30 capsules per bottle
• Total SANA per Bottle: 3,000 mg (3 g)
• Other ingredients: Microcrystalline cellulose (MCC, excipient), gelatin capsule shell
• Appearance: Standard gelatin capsule presentation
• Purity: ≥99%
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: SANA (salicylic acid nitroalkene)
• Synonyms: Salicylic acid nitroalkene research compound; nitroalkene-modified salicylic acid; first-in-class creatine-dependent thermogenesis research compound
• Class: Synthetic small molecule; nitroalkene chemistry class; oral metabolic research compound; first-in-class creatine-dependent thermogenesis pathway research tool
• Chemistry: Salicylic acid backbone with nitroalkene functional group modification
• Recent research literature: Characterized in Phase 1a/b clinical research published in Nature Metabolism (2024) for early metabolic research endpoints
• Regulatory status: Early-stage investigational research compound; not approved by FDA, Health Canada, or any regulatory authority for any indication
• Molecular Weight: Verify against batch COA (novel compound; commodity database values may not match batch material)
• CAS: Verify against batch COA
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications by FDA, Health Canada, or any regulatory authority.
- Early-stage investigational research compound only — SANA has been characterized in only early-phase clinical research and remains an investigational compound. Long-term safety data has not been established.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the capsule label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each batch, regardless of what the label or product image indicates. For novel compounds like SANA, we prioritize structural verification via mass spectrometry against published academic literature.
Third-Party Testing
• [COA links for the SANA 100mg × 30 capsule batch to be added once analytical testing is complete, including MS structural verification against published research literature]
